We serve Chemical Name:3-Methylisonicotinaldehyde CAS:74663-96-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-Methylisonicotinaldehyde
CAS.NO:74663-96-0
Synonyms:4-Pyridinecarboxaldehyde, 3-methyl-;3-methylpyridine-4-carbaldehyde;3-methyl-4-pyridinecarbaldehyde;3-Methyl-4-pyridinecarboxaldehyde;3-Methyl-4-formyl-pyridin;3-Methyl-pyridine-4-carbaldehyde;3-Methylpyridine-4-carboxaldehyde;3-Methylisonicotinaldehyde
Molecular Formula:C7H7NO
Molecular Weight:121.137
HS Code:2933399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:230.2±20.0 °C at 760 mmHg
Density:1.1±0.1 g/cm3
Index of Refraction:1.563
PSA:29.96000
Exact Mass:121.052765
LogP:0.89
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-Pyridinecarboxaldehyde, 3-methyl- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Methylisonicotinaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Pyridinecarboxaldehyde, 3-methyl- Use and application,3-Methyl-4-formyl-pyridin technical grade,usp/ep/jp grade.
Related News: The Institute for Clinical and Economic Review (ICER) on Friday released its report examining the cost-effectiveness of Soliris, also known as eculizumab, as well as up-and-comer efgartigimod for patients with the myasthenia gravis. 6-Hydroxy-benzo[h]chromeno[5,4,3-cde]chromene-5,12-dione manufacturers BetterUp is appointing several behavioral scientists, engineers, account executives, marketers, and operations professionals in the region to accelerate product innovation tailored to the European market. The company’s total European headcount is expected to reach 150 in the next year, including representation in France, Benelux, and Sweden. 2-NITROFURAN suppliers The most frequently reported adverse events for anifrolumab in the TULIP-1 and TULIP-2 trials were upper respiratory tract infection, bronchitis, infusion-related reactions and herpes zoster. 4-[chloro(difluoro)methoxy]benzoic acid vendor & factory.
